Get the Weekly Intelligence Brief — top committee picks every Sunday.
VREX · NASDAQ · STOCK

Varex Imaging Corporation

Healthcare Updated August 11, 2026
$18.60
52W $9.09 – $18.63
57/100
$782.22M
35.4
0.88
AI Committee Verdict
Watch
57/100
Conviction: Contested · 50% agreement · 4 analysts
Contested

Is VREX Bullish or Bearish?

Mixed. Innellis AI committee rates Varex Imaging Corporation (VREX) Watch with a composite score of 57/100 , based on 4 analysts with 50% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +2.73 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -17.27 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 77.9% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • RSI at 97 is in overbought territory — Technical
  • Price trading above the upper Bollinger Band -- stretched — Technical
  • Weekly RSI at 89 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 77.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
4
Conviction
Contested
Sector Rank
Top 68%
of 192 Healthcare peers
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 97 is in overbought territory
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 77.9% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
55 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
96.6
Overbought
MACD Histogram
0.745
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
1.21
Above Upper Band
Price vs Moving Averages
EMA 9
$14.26 Above
EMA 21
$12.61 Above
EMA 50
$11.61 Above
EMA 200
$11.36 Above

Fundamental Analysis

Valuation
72
Profitability
12
Financial Health
94
Cash Flow
15
Valuation
P/E Ratio 35.4×
P/B Ratio 1.58×
PEG Ratio 0.21
Dividend Yield 0.00%
52W High $18.63
52W Low $9.09
Quality & Growth
ROE -1487.5%
ROA -634.8%
Gross Margin 3432.4%
Operating Margin 834.7%
Revenue Growth YoY
Debt / Equity 0.75
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 35.4 (rich relative to a 15-40x range); Price-to-book of 1.6x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -14.9%; Return on assets of -6.3%; Net margin of 2.6%; Gross margin of 34.3%; Current ratio of 3.38 (healthy short-term liquidity); Debt-to-equity of 0.75; Free cash flow per share is negative (-0.48); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full VREX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore VREX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime